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Abstract. The -site amyloid- protein precursor (APP) cleaving enzyme-1 (BACE1) is the rate limiting enzyme in the
generation of amyloid- peptide (A) from APP, one of the major pathways in Alzheimer’s disease (AD) pathology.
Increased BACE1 levels and activity have been reported in the brain of patients with sporadic AD. Therefore, changes
of BACE1 levels in the cerebrospinal fluid (CSF) have also been investigated as a possible biomarker of the disease. We
analyzed BACE1 levels in CSF of elderly healthy participants before and after chronic treatment with a BACE inhibitor
(BACEi) and evaluated the correlation between BACE1 levels and downstream AD markers. Overall, BACE1 CSF levels
showed strong correlations to all downstream AD markers investigated. This is the first reported finding that shows BACE1
levels in CSF were well correlated to its end product A1-42. As previously described, BACE1 levels were strongly correlated
to total-tau and phosphorylated tau levels in CSF. Generally, chronic BACE inhibition did not influence BACE1 CSF protein
levels. Follow-up studies including early-stage AD pathophysiology and prodromal AD patients will help to understand the
importance of measuring BACE1 routinely in daily clinical practice and AD clinical trials.
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INTRODUCTION33
Pathological changes in amyloid- peptide (A),34
total tau (t-tau), and hyperphosphorylated tau (p-tau)35
in cerebrospinal fluid (CSF) can be detected many36
years before neurodegeneration and clinical signs of37
dementia are observed in Alzheimer’s disease (AD)38
patients (reviewed in [1]). Although previous stud-39
ies have shown that these CSF specific markers are40
well associated with the brain pathology and consti-41
tute reliable diagnostic biomarkers of AD [2–8], new42
biomarkers would be of additional value to predict43
disease progression, also in the early disease stages,44
in order to stratify patients and to evaluate treatment45
efficacy.46
-site amyloid precursor protein (APP) cleaving47
enzyme1 (BACE1) is the rate limiting enzyme in the48
generation of A from APP [9, 10], one of the major49
pathways in AD pathology. APP can be cleaved50
by -secretase or -secretase within the extracellular51
domain resulting in the production of large soluble52
APP derivatives (sAPP and sAPP, respec-53
tively) and membrane-bound carboxyl-terminal frag-54
ments (CTF or CTF, respectively). Subsequently,55
-secretase cleaves APP within its transmembrane56
domain, producing either a 3 kDa product p3 from the57
CTF in the non-amyloidogenic pathway, or A from58
the CTF in the amyloidogenic pathway (reviewed59
in [11]). Increased BACE1 levels and activity have60
been reported in the brain of patients with sporadic61
AD [12–16]. Therefore, changes of BACE1 levels62
in the CSF have also been investigated as a possible63
biomarker of the disease (reviewed in [17]).64
Previous investigations measuring the activity or65
protein levels of BACE1 in CSF have resulted in dif-66
ferent conclusions and despite BACE1 being the rate67
limiting step in A formation no direct correlation68
between BACE1 and its end product (A1-42) could69
be established in non-diseased or diseased popula-70
tions. Some studies observed an increase of BACE171
activity in CSF of AD patients versus non-demented72
subjects and other dementias [18–20] as well as a73
higher BACE1 activity in mild cognitive impaired74
(MCI) compared to AD patients [20, 21]. Other75
groups reported no differences between controls,76
MCI, and AD patients [22, 23] and some others even77
reported a decrease of BACE1 activity in CSF of AD78
[24] and multiple sclerosis patients [25]. Concerning79
BACE1 CSF levels, Zhong et al. [21], and Ewers et al.80
[20] reported increased levels of soluble BACE1 in81
MCI patients versus AD and non-demented controls.82
Another study revealed a mild increase in BACE183
levels in AD but also in other neurological disorders 84
associated with inflammation such as autoimmune 85
limbic encephalitis [26], suggesting BACE1 level in 86
CSF is not a specific biomarker for the diagnosis 87
of AD. Interestingly, several groups have reported a 88
strong correlation between BACE1 levels and the lev- 89
els of t-tau [22, 23, 26–28] and p-tau [22, 23, 26, 28] 90
in CSF and associated it to a possible link between 91
BACE1 and neurodegeneration [22, 26–28]. 92
Inhibitors of BACE1 prevent the formation of 93
A1-42 as well as A1-40, A1-38, and A1-43 and 94
would be potential therapeutic agents in the treat- 95
ment of AD. JNJ-54861911 is a potent orally active 96
brain-penetrant BACE inhibitor (BACEi) developed 97
by Janssen Research & Development in collaboration 98
with Shionogi. In Phase I placebo-controlled single 99
and multiple ascending dose studies in healthy elderly 100
and young participants, JNJ-54861911 administered 101
once daily (QD) achieved significant and sustained 102
reduction in CSF A (up to 95% at 90 mg QD 103
for 14 days) and was safe and well tolerated with- 104
out significant adverse events across the dose range 105
investigated (5 mg–150 mg). As such, these results 106
supported confirmation of target engagement of JNJ- 107
54861911 (reduction in A1-40 levels in plasma and 108
CSF) through its peripheral and central BACE1 inhi- 109
bition [29]. 110
Given the current debate regarding the potential of 111
BACE1 as a biomarker for AD and therapeutic target 112
for the disease, we evaluated the correlation between 113
BACE1 levels and downstream protein markers of 114
APP metabolism and neuronal degeneration in CSF 115
and analyzed BACE1 dynamics in CSF of elderly 116
healthy individuals before and after chronic treatment 117
with a BACEi. 118
METHODS 119
Study population 120
The study population considered for this analy- 121
sis consisted of 38 elderly men or women (55–75 122
years; BMI: 18 to 32 kg/m²) enrolled in a double 123
blind, multiple ascending dose (MAD) study to deter- 124
mine the safety, tolerability, pharmacokinetics, and 125
central nervous effects of the BACEi JNJ-54861911 126
in healthy participants. The study consisted of a 4- 127
week screening period, a 14-day treatment phase, 128
and a follow-up period of 7 to 14 days after last 129
dose administration. Elderly participants were con- 130
sidered healthy based on medical history, physical 131
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examination, 12-lead ECGs, and clinical laboratory132
evaluations. In the MAD study, elderly participants133
received double-blind JNJ-54861911 (n= 6/cohort)134
or placebo (n= 2/cohort) as oral suspension at esca-135
lating doses of 5, 30, 50, or 90 mg QD or open label136
JNJ-54861911 as solid dose formulation of 25 mg QD137
(n= 6) for 14 days.138
The elderly participants included in the current139
analyses are a sub-sample of the study population140
enrolled in the MAD study, i.e., all elderly partici-141
pants from whom CSF has been collected. Details of142
the study design have been described earlier [29].143
The MAD study was conducted from June 2013144
to December 2013 at SGS, Life Science Services,145
Clinical Pharmacology Unit, Belgium. The study146
protocol and its amendments were reviewed and147
approved by an Institutional Review Board (Com-148
missie voor Medische Ethiek, Ziekenhuis Netwerk149
Antwerpen [ZNA], Antwerp, Belgium). All proce-150
dures followed were in accordance with the principles151
of the Declaration of Helsinki. Written informed152
consent was obtained from all participants before153
participation. The study is registered on ClinicalTri-154
als.gov: NCT01887535.155
APOE 4 genotyping156
From all participants, a blood sample for phar-157
macogenomic analysis (10 mL) was collected in158
tubes containing potassium/sodium EDTA. DNA was159
isolated using Puregene chemistry and automated160
extraction using an Autopure LS. For all participants,161
APOE 4 carrier status was analyzed in a multiplex162
reaction using polymerase chain reaction/ligation163
detection reaction [30].164
CSF collection and processing165
For all elderly participants, a baseline CSF sample166
(12 mL) was collected predose on Day 1 (between167
6:00 and 9:00 AM) in fasting condition by a sin-168
gle lumbar puncture between the L3 and L4 or L4169
and L5 intervertebral space. Serial CSF sampling170
(4 mL/sample) was performed through an indwelling171
subarachnoid lumbar catheter from 2 h before and172
until 36 h after the last dosing, as described previously173
[29, 31]. CSF samples were collected in polypropy-174
lene tubes and aliquoted by immediate transfer of175
500L samples to multiple storage tubes (Micronic176
1.4 ml non-coded tubes U-bottom in Comorack-96,177
Cat No. MP22502 with caps from FluidX, Split TPE178
Capcluster Blue. Cat. No. 65-53028) and stored at179
–70◦C immediately after collection. All samples ana- 180
lyzed in this study had at most two freeze-thaw 181
cycles. 182
Bioanalytical methods 183
Analysis of BACE1 184
BACE1 levels in CSF were analyzed using a 185
BACE1 sandwich ELISA as previously described 186
[26]. Briefly, NUNC ninety-six-well plates (Life 187
Technologies) were coated with 50l/well of cap- 188
ture antibody (5G7 [32]) dissolved in coating buffer 189
(10 mM Tris-HCl, 10 mM NaCl, 10 mM NaN3, 190
pH 8.5) with a final concentration of 2g/ml. 191
After overnight incubation at 4◦C, the plates were 192
washed with PBS+0.05% Tween 20 and blocked 193
with 100l/well of casein buffer (1 g casein in 1 L 194
PBS, pH7.4) for 4 h at room temperature. The coat- 195
ing was always done the day before the actual 196
experiment. Samples or standards were diluted in 197
casein buffer and mixed with the detection anti- 198
body (10B8-HRPO [32], 10 mg/ml) diluted 1:2000 199
in casein buffer. The mixtures were added to the 200
ELISA plates and incubated overnight at 4◦C. Plates 201
were washed and developed with 0.2 mg/ml of 202
3,5,3’,5’-tetramethyl-benzidine (TMB, Sigma) dis- 203
solved in 100 mM sodium acetate (NaAc, pH 4.9) 204
supplemented with 0.03% H2O2. The reactions were 205
allowed to proceed for maximum 15 min on a plate 206
shaker at room temperature. The reactions were 207
stopped by adding 2 N H2SO4, 50l/well and the 208
plates were read on a Perkin Elmer Envision 2103 209
multilabel reader at 450 nm. The anti-BACE1 mon- 210
oclonal antibodies (mAbs) 5G7 and 10B8 were 211
generated as described before [32]. These mAbs are 212
highly specific for BACE1 and do not cross react 213
with BACE2 or other structurally related aspartyl 214
proteases [26, 32]. BACE1 levels were determined 215
using a standard curve with a 4-parameter logistic 216
model with 1/Y2 weighting function. All samples 217
from each participant were analyzed in duplicate on 218
the same assay plate. Only mean values with repli- 219
cate well coefficient of variation (CV) of≤20% were 220
accepted. 221
Analysis of Aβ1-37 , Aβ1-38 , Aβ1-40 , and Aβ1-42 222
concentrations (MSD 4-plex) 223
A qualified prototype multiplex immunoassay 224
based on Meso Scale Discovery (MSD) (Gaithers- 225
burg, MD, USA) electrochemiluminescence (ECL) 226
detection technology was utilized for simultaneous 227
detection of four A species (A1-37, A1-38, A1-40 228
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and A1-42). This method has been described previ-229
ously [33, 34]. Briefly, the MSD 4-plex assay utilizes230
four different Janssen monoclonal antibodies with231
specificity for four different A isoforms (A1-37,232
A1-38, A1-40, and A1-42) and allows simultane-233
ous quantification of these four A species in CSF.234
For all analytes, the lower and higher limit of quanti-235
tation were determined to be 4.57 and 10,000 pg/mL,236
respectively. Percentage cross-reactivity, defined as237
(mean predicted concentration/tested peptide con-238
centration)*100, was shown to be < 1% for all239
combinations of antibodies and peptides tested.240
Detection was performed with labeled Janssen241
human-specific anti-A antibody JRF/AN/25 with242
specificity for A isoforms with intact N-terminus,243
i.e., full-length A. A concentrations were deter-244
mined using a standard curve with 4-parameter245
logistic model with 1/Y2 weighting function. All246
samples from each participant were analyzed in247
duplicate on the same assay plate. Only mean values248
with replicate well CV of≤20% were accepted.249
Analysis of sAβPP concentrations250
sAPP, sAPP, and sAPP total were quanti-251
fied in CSF using MSD ECL detection technology.252
sAPP and sAPP CSF concentrations were253
measured using MSD® 96-well MULTI-SPOT®254
sAPP/sAPP assay according to manufacturer’s255
instructions [35].256
For sAPP total, an MSD ECL assay devel-257
oped by Janssen Research & Development was used258
[29]. In brief, the assay uses P2-1 (against amino259
acid 104–118 of human APP695) as capturing260
antibody, and SULFO-TAGTM labeled anti-sAPP261
JRD/sAPP/23, raised against the peptide sequence262
of amino acids 557–576 of human APP695, as263
detection antibody. Briefly, 96-well SECTOR® stan-264
dard plates were pre-wetted with PBS for 3 min265
and tapped dry, where after plates were coated with266
1.25g/mL capture antibody overnight at 4◦C. After267
a wash, plates were blocked and washed again. Next,268
25L of standards or samples was applied, and the269
plate was incubated for 1 h at room temperature on270
a shaker. After the next washing step, 25L of the271
detection antibody (20g/mL) was added per well272
for an additional incubation step of 1 h. After the273
next wash step, read buffer was added to all wells,274
followed by 10 min of incubation. The plate was read275
with the Sector Imager 6000 (MSD).276
The sAPP levels were determined using a stan-277
dard curve with 4-parameter logistic model with278
1/Y2 weighting function. All samples from each279
participant were analyzed in duplicate on the same 280
assay plate. Only mean values with replicate well CV 281
of≤20% were accepted. 282
Analysis of baseline CSF Aβ1-42 , P-tau181P, and 283
T-tau levels 284
Baseline A1-42, phosphorylated tau at posi- 285
tion threonine 181 (P-tau181P) and total tau (T-tau) 286
concentrations were measured using INNO-BIA 287
AlzBio3 kit reagents (Innogenetics now Fujirebio 288
Europe, Ghent Belgium) and Luminex analytical 289
platform [36, 37] with predefined assay acceptance 290
criteria of CV <25% for duplicates [36]. Diagnostic 291
threshold CSF concentrations for AD versus normal 292
controls for A1-42 were applied to current sample 293
set to judge the likelihood of having cerebral amyloid 294
plaque deposition [36, 37]. 295
Statistical analysis 296
Baseline CSF concentrations of BACE1 were 297
compared with amyloid downstream markers, mark- 298
ers of neurodegeneration and other baseline and 299
demographic characteristics with Pearson correla- 300
tion coefficients and linear regression. The percent 301
change from baseline in CSF BACE1 concentra- 302
tions after 14 days of treatment, 24-h post-dose, were 303
computed. The relationships between the changes 304
in CSF BACE1 with other factors were analyzed 305
with an F-test. All analyses were performed using 306
SAS statistical software version 9.2 (SAS Institute, 307
Cary, NC). 308
RESULTS 309
Demographic characteristics 310
Demographic characteristics, APOE 4 status, 311
and pooled baseline CSF concentrations of BACE1 312
and all amyloid downstream markers and markers 313
of neurodegeneration are summarized in Table 1. 314
Thirty-eight elderly men and women (mean age 66.3 315
y) were enrolled and completed the study. Overall, 316
65.8% (n= 25/38) of subjects enrolled were male 317
and 26.3% (n= 10/38) were identified as APOE 4 318
carriers (Table 1). Pooled CSF BACE1 mean (SD) 319
concentration was 4.4 (1.72) ng/mL and compara- 320
ble to the 6.6 (0.7) ng/mL value reported by Bara˜o 321
et al. [26] for non-neurological disorder controls. 322
Four participants had baseline A1-42 concentra- 323
tions below the threshold (249 pg/mL), suggestive of 324
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Table 1
Demographics and baseline cerebrospinal fluid (CSF) biomarker
concentrations for study participants
Demographic and Baseline Characteristics for CSF
Cohorts: ALZ1002
Pooled CSF Subjects
ALZ1002
n 38
Sex, Male, n (%) 25 (65.8%)
Age, years
Mean (SD) 66.3 (5.93)
Median (Range) 67 (55, 74)
Race, White, n (%) 36 (94.7%)
APOE E4 Carrier Status, n (%)
No 28 (73.7%)
Yes 10 (26.3%)
A1-37, pg/mL, n 38
Mean (SD) 526.2 (157.53)
Median (Range) 506 (291, 975)
A1-38, pg/mL, n 38
Mean (SD) 2977.1 (925.54)
Median (Range) 2975 (1650, 6030)
A1-40, pg/mL, n 38
Mean (SD) 11143.2 (3301.40)
Median (Range) 10300 (6720, 21200)
A1-42, pg/mL, n 38
Mean (SD) 908.8 (337.02)
Median (Range) 924 (321, 2200)
A1-42/A1-40 Ratio, n 38
Mean (SD) 0.08 (0.024)
Median (Range) 0.08 (0.02, 0.13)
A1-42 (AlzBio3), pg/mL, n 37
Mean (SD) 364.2 (76.86)
Median (Range) 380 (137, 474)
T-tau, pg/mL, n 35
Mean (SD) 71.3 (42.44)
Median (Range) 57 (34, 213)
P-tau181, pg/mL, n 37
Mean (SD) 32.4 (15.83)
Median (Range) 28 (17, 106)
sAPP Total, ng/mL, n 38
Mean (SD) 1248.1 (433.21)
Median (Range) 1169 (555, 2140)
sAPP alpha, ng/mL, n 38
Mean (SD) 182.8 (64.67)
Median (Range) 181 (75, 351)
sAPP, ng/mL, n 38
Mean (SD) 262.2 (88.81)
Median (Range) 246 (124, 482)
BACE-1, ng/mL, n 38
Mean (SD) 4.4 (1.72)
Median (Range) 3.9 (2.0, 10.0)
cerebral amyloid plaque deposition [37], but none had325
elevated T-tau or P-tau181P values (data not shown).326
Correlation between BACE1 and APOE 4327
status, gender, and age328
Correlation analyses were performed between CSF329
BACE1 and APOE 4 status, gender, and age. CSF330
Fig. 1. Correlation of -site APP-cleaving enzyme-1 (BACE1)
protein levels in CSF with age in healthy elderly participants.
A Pearson correlation coefficient was calculated to evaluate the
possible correlation between BACE1 and age. Regression line
R2 = 0.1114; statistical significant level was set at 0.05. n= 38;
rho = 0.33; p= 0.0406.
BACE1 levels showed a weak positive correlation 331
with age (r= 0.33: p= 0.0405; Fig. 1), but not with 332
APOE 4 status or gender (data not shown). 333
Correlation between BACE1 and Aβ1-37 , Aβ1-38 , 334
Aβ1-40 , and Aβ1-42 (MSD 4-plex) 335
CSF BACE1 levels for all participants combined 336
(APOE 4 carriers and non-carriers; Fig. 2A, D, 337
G, J) correlated strongly and significantly with 338
A1-37 (r= 0.843; p< 0.0001), A1-38 (r= 0.862; 339
p< 0.0001), and A1-40, (r= 0.869, p< 0.0001); 340
and moderately with A1-42 (r= 0.497; p= 0.002). 341
Despite the small sample size of APOE 4 carri- 342
ers, strong and significant correlations with BACE1 343
were observed in this small subgroup for A1-40, 344
(r= 0.821; p= 0.004; Fig. 2E), A1-38 (r= 0.865; 345
p= 0.001; Fig. 2H), and A1-37 (r= 0.864; p= 0.001; 346
Fig. 2K). Separation of APOE 4 carriers and non- 347
carriers did not influence the correlation coefficients 348
for A1-40,1-38,1-37 species (Fig. 2F, I, L). The cor- 349
relation between BACE1 and A1-42 was moderate 350
and significant in noncarriers (r= 0.567; p< 0.002; 351
Fig. 2C) but weak and non-significant in the carrier 352
group (r= 0.121; p= 0.740; Fig. 2B) which was likely 353
due to the small sample size of APOE 4 carriers in 354
the analysis group. 355
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Fig. 2. Correlation of -site APP-cleaving enzyme-1 (BACE1) protein levels with A species (A1-42, A1-40, A1-38, A1-37) at baseline
in CSF of healthy elderly for all participants (A, D, G, J), for APOE 4 allele carriers (B, E, H, K), and for APOE 4 non-carriers (C, F,
I, L) measured by MSD4-plex assay system. A Pearson correlation coefficient was calculated to evaluate the possible correlation between
BACE1 and A1-42 (A-C); between BACE1 and A1-40 (D-F); between BACE1 and A1-38 (G-I); and between BACE1 and A1-37 (K-L)
for all, APOE 4 carrier and non-carriers, respectively. Number of participants for whom samples could be analyzed and for which levels
were above LOQ are indicated below each panel. p< 0.05 was set as a statistically significant level.
Un
co
rre
cte
d A
uth
or
 P
ro
of
M. Timmers et al. / Correlations between BACE1 and Downstream Markers of AD 7
Correlation between BACE1 and sAβPPα,356
sAβPP-β, and sAβPP-total357
Within this overall elderly population, CSF358
BACE1 levels correlated significantly and pos-359
itively with sAPP-total (r= 0.878; p< 0.0001;360
Fig. 3A), sAPP (r= 0.5227; p= 0.0008; Fig. 3D)361
and sAPP (r= 0.5871; p= 0.0001; Fig. 3G).362
These moderately strong correlations with sAPP363
remained when evaluating APOE 4 carriers364
(n= 10) (sAPP [r= 0.6403; p= 0.0461]; sAPP365
[r= 0.6195; p= 0.0561); sAPP-total [r= 0.6230;366
p= 0.0543]). Correlations and significance levels367
remained unchanged in the APOE 4 non-carrier368
group (Fig. 3C, F, I).369
Correlations between BACE1 and Aβ1-42 ,370
P-tau181P and T-tau levels (AlzBio3)371
Moderately strong and significant positive correla-372
tions between CSF BACE1 and p-tau181P (r= 0.4406;373
p= 0.0063; Fig. 4D) and t-tau (r= 0.7355; p< 0.0001;374
Fig. 4G) were observed in this elderly population,375
while CSF A1-42 as measured with the AlzBio3376
assay did not correlate with BACE1 (r= 0.0305;377
p= 0.8575; Fig. 4A). Separation of carriers and non-378
carriers did not result in significant correlations with379
t-tau or p-tau181P for APOE 4 carriers (Fig. 4B, E,380
H) perhaps due to its small sample size, while correla-381
tions were maintained for the APOE 4 non-carriers382
(Fig. 4C, F, I).383
CSF BACE1 dynamics upon chronic inhibition384
with JNJ-54861911385
Overall treatment for up to 14 days with increas-386
ing dose levels (ranging from 5 to 90 mg) of the387
BACE inhibitor JNJ-54861911 did not influence388
CSF BACE1 protein levels as depicted in Fig. 5A389
(p= 0.5313).390
However, it was noted that some individual par-391
ticipants (8/38; all APOE 4 non-carriers) showed392
increases in CSF BACE1 protein levels ranging from393
24 to 132% (Table 2) independent of dose level394
administered. None of these individuals had showed395
low CSF baseline levels of A1-42 suggestive of396
absence of cerebral amyloid plaque deposition. Fur-397
ther investigation did not show a correlation between398
baseline biomarker levels (A (all forms), sAPP,399
sAPP, sAPP total, t-tau, p-tau181p) and change400
in CSF BACE1 from baseline that could poten-401
tially clarify these increases. Similar findings have402
been observed upon acute dosing with JNJ-54861911 403
(dose levels ranging from 1 to 150 mg) in the single 404
ascending dose study of JNJ-54861911 (see Supple- 405
mentary Figure 1 and Supplementary Table 1), with 406
the exception that individual participants showing 407
increases >20% of CSF BACE1 protein levels upon 408
dosing were identified as both APOE 4 carriers and 409
non-carriers (Supplementary Table 1). 410
DISCUSSION 411
Identification of new biomarkers may enhance 412
efforts to diagnose AD in an early stage, to strat- 413
ify patients, and to better evaluate treatment efficacy. 414
Since BACE1 is the rate limiting enzyme in the gener- 415
ation of A from APP [9, 10] and increased BACE1 416
levels and activity have been reported in the brain 417
of patients with sporadic AD [12–16], changes of 418
BACE1 levels in the CSF have been investigated as a 419
possible biomarker of the disease (see Barao et al. for 420
a review [17]). We analyzed BACE1 dynamics in CSF 421
of elderly healthy individuals before and after chronic 422
inhibition of BACE and evaluated its correlation to 423
the well-known downstream AD markers to better 424
understand the potential benefit of measuring BACE1 425
routinely in the clinics as a potential diagnostic or 426
treatment effect biomarker for AD. 427
Savage et al. [23] reported that BACE1 activity 428
increased approximately 1.8%/year in healthy con- 429
trols but not in AD or MCI groups. However, in this 430
cohort of healthy elderly individuals a weak correla- 431
tion is observed between BACE1 CSF levels and age 432
suggesting that BACE1 levels are minimally affected 433
by age. Although increased BACE1 CSF activity has 434
been associated with APOE 4 genotype in subjects 435
with MCI and AD [20], no significant correlation is 436
observed between BACE1 levels and APOE 4 status 437
in healthy elderly individuals. The lack of such corre- 438
lation is supported by similar findings by Zetterberg 439
et al. [27], Mulder et al. [22], and Savage et al. [23], 440
who found no evidence that number of APOE 4 alle- 441
les among all diagnostic groups had any impact on 442
mean BACE1 activity. 443
BACE1 CSF protein levels show strong corre- 444
lations to all downstream AD markers including 445
A1-37, A1-38, A1-40, A1-42, total sAPP, 446
sAPP, and sAPP suggesting there is an 447
upstream metabolic pathway that can regulate the 448
concentration of these metabolites together. Interest- 449
ingly, APOE 4 carriers show a tendency for strong 450
correlations for A forms except A1-42. However, 451
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Fig. 3. Correlation of -site APP-cleaving enzyme-1 (BACE1) protein levels with sAPP total (A-C), sAPP (D-F), and sAPP (G-I)
at baseline in CSF of healthy elderly for all participants (A, D, G), for apolipoprotein (APOE) 4 allele carriers (B, E, H), and for APOE 4
non-carriers (C, F, I). A Pearson correlation coefficient was calculated to evaluate the possible correlation between BACE1 and sAPP total
(A-C); between BACE1 and sAPP (D-F); and between BACE1 and sAPP (G-I) for all APOE 4 carriers and non-carrier participants,
respectively. Number of participants for whom samples could be analyzed and for which levels were above LOQ are indicated below each
panel. p< 0.05 was set as a statistically significant level.
these differences are not significant likely due to the452
small sample size.453
In this study, for the first time, BACE1 levels454
correlate significantly with A1-42 levels in CSF.455
In MCI and AD patients, an inverse relation or no456
relation may be expected as higher BACE1 levels457
in AD patients occur in combination with lower458
A1-42 due to plaque formation, depending on the 459
balance between dynamics of drug treatment and 460
biology of APP processing on BACE1 levels. In 461
healthy subjects, an increase in BACE1 levels would 462
result in increased production of A1-42, consistent 463
with observations in this study. Intriguingly, this cor- 464
relation is not observed when A1-42 levels were 465
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Fig. 4. Correlation of -site APP-cleaving enzyme-1 (BACE1) protein levels with A1-42 (A-C), phosphorylated tau (p-tau181p, D-F), and
total tau (t-tau, G-I) at baseline in CSF of healthy elderly for all participants (A, D, G), for apolipoprotein (APOE) 4 allele carriers (B, E, H),
and for APOE 4 non-carriers (C, F, I) measured by the ALZBio3 (xMAP) assay. A Pearson correlation coefficient was calculated to evaluate
the possible correlation between BACE1 and A1-42 (A-C); between BACE1 and p-tau181p (D-F); and between BACE1 and t-tau (G-I) for
all, APOE 4 carriers and non-carriers, respectively. Number of participants for whom samples could be analyzed and for which levels were
above LOQ are indicated below each panel. p< 0.05 was set as a statistically significant level.
measured by the Alzbio-3 assay but only when the466
A MSD 4-plex assay was used (a moderate corre-467
lation was observed between the AlzBio-3 and MSD468
4-plex assay [Pearson r= 0.659, p> 00001]; data not469
shown). The reason for this discrepancy is currently470
unclear, but might be multifactorial in nature. First 471
of all, matrix effects are known to influence the 472
concentration of A1-42 among immunoassays [38]. 473
The MSD 4-plex assay shows high sensitivity and 474
specificity allowing measurements in diluted samples 475
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Fig. 5. Percent change in BACE1 levels from Day 1 baseline to Day 14 for those with > 20% change of BACE1 protein levels from baseline
following repeated once daily dosing with JNJ-54861911 at 5, 25, 30, 50, and 90 mg or placebo for 14 days. Data are represented as individual
and mean percent change (n= 8/38) in BACE1 from Day 1 baseline to Day 14 (24-h post dose).
thereby reducing actual matrix effects. Secondly,476
both assays employ different antibodies. The Janssen477
antibodies might have differential binding properties478
altering the fraction of detectable A1-42 with the479
MSD 4-plex assay. Thirdly, dissimilar sources for480
the calibrator peptides may lead to divergences in the481
absolute A1-42 concentration. In addition, variable482
correlations between different A1-42 immunoassays483
have been reported before ranging from moderate484
to very strong correlations [39–41]. The correlation485
between BACE1 and A1-40 CSF levels is in line with486
earlier publications where BACE1 CSF activity was487
well correlated to A1-40 CSF levels [22, 27].488
Since sAPP is the direct product from APP489
after BACE1 cleavage, the correlation between490
BACE1 and sAPP CSF levels is not unexpected491
and is in line with the previous results describing492
a strong correlation between sAPP and BACE1493
CSF activity [23, 27, 28]. In contrast, the corre-494
lation between BACE1 and sAPP CSF levels495
appears more surprising. Nevertheless, this correla-496
tion might be explained by the strong correlation497
between sAPP and sAPP CSF levels which498
also suggests that - and -secretase processing of499
APP can be co-regulated processes, as suggested500
by the previous results describing a strong correlation501
between sAPP and BACE1 CSF activity [27].502
As previously reported, we also observed a strong 503
correlation between BACE1 levels and t-tau [22, 23, 504
26–28] and p-tau [22, 23, 26, 28] levels in CSF of 505
elderly healthy individuals. Although high amounts 506
of t-tau and p-tau in CSF have been associated with 507
increased neuronal damage [42–44] and have been 508
considered a general marker for neurodegenerative 509
processes [27, 42–44], in this study we only measured 510
baseline tau levels in elderly healthy individuals and it 511
is difficult to assume a direct link of BACE1 expres- 512
sion to tau hyperphosphorylation and/or tauopathy 513
and therefore to neurodegeneration. Tau is a phospho- 514
rylated protein which explains why t-tau and p-tau 515
are mostly correlated. Since in AD the increase in 516
t-tau and p-tau in CSF correlate well to each other 517
[27, 42, 43, 45], it remains to be established if that 518
is just an increase of “normal” tau overproduced by 519
a neurodegeneration-linked mechanism (e.g., stress 520
response) or if the observed positive correlation in 521
healthy individuals is due to another mechanism (e.g., 522
aging) beyond the scope of this study. 523
Generally, BACE1 CSF protein levels are not 524
affected by acute (see Supplementary Figure 1) or 525
chronic BACE1 inhibition (Fig. 5). However, the 526
observed tendency to increased levels of BACE1 527
in some individual participants could not be linked 528
to changes in other biomarkers. In the MAD study 529
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n. (chronic dose), only APOE 4 non-carriers show sig- 530
nificant changes in BACE1 CSF levels, but in the sin- 531
gle ascending dose study (54861911ALZ1001), both 532
carriers and non-carriers show changes >20%. There- 533
fore, more in depth analysis are needed to further 534
understand the reasons for this individual variation. 535
The relatively small sample size of the healthy 536
elderly cohort in the MAD study can be considered a 537
limitation of the present study, particularly for the low 538
number of APOE E4 carriers when compared to other 539
published studies in patients with AD. Thus, correla- 540
tions of BACE1 for all AD markers were reported for 541
all participants combined (n= 38), APOE E4 carriers 542
(n= 10) and non-carriers (n= 28) separately. Despite 543
the small APOE E4 carrier subgroup, the observed 544
correlations of biomarkers with BACE1 levels were 545
found to be numerically comparable across all sub- 546
groups for all A fragments except A1-42. 547
Conclusions 548
In elderly healthy participants, BACE1 CSF levels 549
show strong to moderate correlations to all down- 550
stream AD markers including A1-42 and markers 551
of neurodegeneration (t-tau and p-tau181p). For the 552
first time, a (moderate) correlation between BACE1 553
levels in CSF and A1-42 is shown. Generally, 554
chronic BACE inhibition does not influence BACE1 555
CSF levels. Additional studies including preclinical 556
(asymptomatic) and prodromal AD cases will help 557
understanding the significance of measuring BACE1 558
routinely in clinical practice and in AD clinical trials. 559
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